The role of paliperidone extended release for the treatment of bipolar disorder

Jehan Marino1, Clayton English2, Joshua Caballero1, Catherine Harrington11College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, 2College of Pharmacy, Albany College of Pharmacy and Health Sciences, Colchester, VT, USABackground: Bipolar disorder (BD) is a chronic, relapsing, episod...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marino J, English C, Caballero J, Harrington C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/3917233d38424cc5890b571a755f4255
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3917233d38424cc5890b571a755f4255
record_format	dspace
spelling	oai:doaj.org-article:3917233d38424cc5890b571a755f42552021-12-02T01:25:55ZThe role of paliperidone extended release for the treatment of bipolar disorder1176-63281178-2021https://doaj.org/article/3917233d38424cc5890b571a755f42552012-04-01T00:00:00Zhttp://www.dovepress.com/the-role-of-paliperidone-extended-release-for-the-treatment-of-bipolar-a9744https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Jehan Marino1, Clayton English2, Joshua Caballero1, Catherine Harrington11College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, 2College of Pharmacy, Albany College of Pharmacy and Health Sciences, Colchester, VT, USABackground: Bipolar disorder (BD) is a chronic, relapsing, episodic mental illness associated with other psychiatric comorbidities. There is a substantial economic burden with BD, which makes it challenging to treat. The aim of this review is to evaluate the pharmacology, clinical efficacy, and safety data related to paliperidone extended release (ER) for the treatment of BD.Methods: A literature search was performed from January 1966 through January 2012 using PreMEDLINE, MEDLINE, EMBASE, IPA, and ClinicalTrials.gov to identify articles in English regarding the pharmacology, clinical efficacy, and safety of paliperidone ER in acute mania or mixed episodes or in the maintenance treatment of BD I.Results: There are currently three published studies relating to the use of paliperidone ER for the treatment of BD. Two of these evaluated paliperidone ER as monotherapy for acute mania, while the other assessed its role as adjunct with a mood stabilizer.Conclusion: According to the limited available evidence, paliperidone at higher doses of ER 9&ndash;12 mg/day may be a safe and efficacious treatment option for acute episodes of mania in BD. A once-daily dose formulation may improve patient adherence to treatment; however, the cost of paliperidone ER, which is higher than that of generically available second-generation antipsychotics (such as olanzapine and risperidone), and a lack of alternative dosage forms (ie, liquid, intramuscular) compared with other agents may limit its usefulness in the treatment of BD. The role of paliperidone ER as an adjunctive agent or for long-term use requires further investigation.Keywords: paliperidone ER, bipolar disorder, clinical efficacy, safetyMarino JEnglish CCaballero JHarrington CDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2012, Iss default, Pp 181-189 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Marino J English C Caballero J Harrington C The role of paliperidone extended release for the treatment of bipolar disorder
description	Jehan Marino1, Clayton English2, Joshua Caballero1, Catherine Harrington11College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, 2College of Pharmacy, Albany College of Pharmacy and Health Sciences, Colchester, VT, USABackground: Bipolar disorder (BD) is a chronic, relapsing, episodic mental illness associated with other psychiatric comorbidities. There is a substantial economic burden with BD, which makes it challenging to treat. The aim of this review is to evaluate the pharmacology, clinical efficacy, and safety data related to paliperidone extended release (ER) for the treatment of BD.Methods: A literature search was performed from January 1966 through January 2012 using PreMEDLINE, MEDLINE, EMBASE, IPA, and ClinicalTrials.gov to identify articles in English regarding the pharmacology, clinical efficacy, and safety of paliperidone ER in acute mania or mixed episodes or in the maintenance treatment of BD I.Results: There are currently three published studies relating to the use of paliperidone ER for the treatment of BD. Two of these evaluated paliperidone ER as monotherapy for acute mania, while the other assessed its role as adjunct with a mood stabilizer.Conclusion: According to the limited available evidence, paliperidone at higher doses of ER 9&ndash;12 mg/day may be a safe and efficacious treatment option for acute episodes of mania in BD. A once-daily dose formulation may improve patient adherence to treatment; however, the cost of paliperidone ER, which is higher than that of generically available second-generation antipsychotics (such as olanzapine and risperidone), and a lack of alternative dosage forms (ie, liquid, intramuscular) compared with other agents may limit its usefulness in the treatment of BD. The role of paliperidone ER as an adjunctive agent or for long-term use requires further investigation.Keywords: paliperidone ER, bipolar disorder, clinical efficacy, safety
format	article
author	Marino J English C Caballero J Harrington C
author_facet	Marino J English C Caballero J Harrington C
author_sort	Marino J
title	The role of paliperidone extended release for the treatment of bipolar disorder
title_short	The role of paliperidone extended release for the treatment of bipolar disorder
title_full	The role of paliperidone extended release for the treatment of bipolar disorder
title_fullStr	The role of paliperidone extended release for the treatment of bipolar disorder
title_full_unstemmed	The role of paliperidone extended release for the treatment of bipolar disorder
title_sort	role of paliperidone extended release for the treatment of bipolar disorder
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/3917233d38424cc5890b571a755f4255
work_keys_str_mv	AT marinoj theroleofpaliperidoneextendedreleaseforthetreatmentofbipolardisorder AT englishc theroleofpaliperidoneextendedreleaseforthetreatmentofbipolardisorder AT caballeroj theroleofpaliperidoneextendedreleaseforthetreatmentofbipolardisorder AT harringtonc theroleofpaliperidoneextendedreleaseforthetreatmentofbipolardisorder AT marinoj roleofpaliperidoneextendedreleaseforthetreatmentofbipolardisorder AT englishc roleofpaliperidoneextendedreleaseforthetreatmentofbipolardisorder AT caballeroj roleofpaliperidoneextendedreleaseforthetreatmentofbipolardisorder AT harringtonc roleofpaliperidoneextendedreleaseforthetreatmentofbipolardisorder
_version_	1718403065635143680

The role of paliperidone extended release for the treatment of bipolar disorder

Ejemplares similares